Image

TINO: T Cells in the Nose of Older Adults

TINO: T Cells in the Nose of Older Adults

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Rationale: Individuals with advanced age are at a progressively increasing risk of acquiring lower respiratory tract infections. Besides calendar age, the degree of frailty also associates with increased susceptibility to pneumonia requiring hospitalization. How alterations in the mucosal immune system with advanced age predispose to infections remains unclear as access to relevant tissue samples is limited. With minimally-invasive nasal sampling methods, it was recently observed that in vital older adults, both CD4+ T cells and CD8+ T cells are selectively lost from the nasal mucosa. However, the exact phenotype, underlying mechanisms, key molecules and consequences of this have not yet been investigated.

Objective

Elucidate the mechanisms underlying the loss of nasal T cells and characterize in depth the differences of T cells in young and older adults and associate this loss with susceptibility to infections.

Study design: Prospective cohort study

Study population: Participants will be recruited from 3 groups:

  • healthy young adults (18-30 years, n=50)
  • vital older adults (>65 years, n=60)
  • frail elderly (>65 years, n=60). This group includes individuals without a history of recurrent respiratory infections or with >2 self-reported episodes of respiratory infection in the past year.

Main study parameters/endpoints: Frequency of nasal CD8+ T cells in young adults and frail older adults.

Secondary study parameters/endpoints:

  • Phenotype (subsets, activation status), functionality, transcriptomic state, clonality and frequency of nasal and blood T cell populations
  • Stability of T cells and other immune parameters, as described for main study parameter, during a second sample after 3 months.
  • Analysis of other immune populations as for main study parameter
  • Concentration of nasal and systemic factors (e.g. cytokines and metabolites) and their association with T cells and other immune populations
  • Respiratory tract microbiota profiles and presence of asymptomatic viral infections and their association with T cells and other immune parameters
  • Chronological and biological age, sex, and other immunologically relevant parameters with T cell populations and other immune parameters
  • Alteration of T cell phenotype, during and following respiratory tract infections. Levels of antigen-specific T cells and other immune parameters in nose and blood post infection.

Eligibility

Inclusion Criteria:

•Adults able and willing to provide informed consent.

Specific inclusion criteria per group:

  • Young adults aged 18-30 years old
  • Healthy elderly aged >65 years old
  • Frail elderly >65 years old
  • Clinical Frailty score healthy elderly 1-3
  • Clinical Frailty score frail elderly >3
  • Self-reported respiratory tract infection in previous year healthy elderly 0-1
  • Self-reported respiratory tract infection in previous year frail elderly 0-1 or >1

Exclusion Criteria:

  • Incompetence to provide informed consent prior or during study
  • Current smoker or >40 pack year history
  • History of severe nose bleedings
  • Diagnosed with asthma, COPD or chronic rhinosinusitis
  • Use of inhalation corticosteroids or antibiotics in the past 6 weeks
  • Current use of anti-coagulants (to prevent nosebleeds). Platelet inhibitors like acetylsalicylzuur (Ascal) are allowed.
  • Respiratory tract infection or common cold in the past 2 weeks
  • Immunocompromised individuals (with primary immune deficiency or secondary immune deficiency)
  • Life expectancy <28 days in the opinion of study physician
  • Vaccination in the 2 months prior to study start. A potential subject that is only excluded from participation based on a recent vaccination will be asked to re-participate 2 months post vaccination.

Study details
    Respiratory Tract Infections
    Aging

NCT06039527

Leiden University Medical Center

24 June 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.